Loading…
← CockpitCompetitor Analysis › AVIR Atea Pharmaceuticals, Inc.Open in the cockpit ↗

Atea Pharmaceuticals, Inc.AVIRCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 30
Mkt cap
$320M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$1.26M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$3.99
1D+0.8%
1W-5.5%
1M-10.6%
3M-25.6%
6M-4.8%
YTD+11.8%
1Y+32.1%
ATR %6.2%
Beta0.87
52w lowhigh38.1% off high

What Atea Pharmaceuticals does

Employees: 55

Atea Pharmaceuticals at a glance

Size Atea Pharmaceuticals (AVIR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $320M, the 3026th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.99 on 18 Nov 2026.

Performance Over six months the shares fell 4.8%, against -22.1% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.

Short interest Short interest is 3.8% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026AVIR 94Peer median 77
Six months, rebased to 100: Atea Pharmaceuticals against the median of its 20 peers (local-currency closes).

Atea Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$416,000-$416,000-$416,000-$416,000-$260,000
EBITDA-$172M-$180M-$193M-$164M-$130M
Net income-$155M-$158M-$168M-$136M-$116M
Free cash flow-$141M-$132M-$135M-$85.4M-$123M
Capital expenditure$0$0$0$0$1.94M
Total debt$213,000$843,000$1.64M$2.40M$3.12M

Quarterly statements and history in the cockpit →

Atea Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%005250SECARE6576368AINO600538002168INDSWFTLAB1720ALEMBICLTDMYX301331SOLARARLMDAVIR6-month return →1-month return →
Up and to the right = strong over both horizons. Atea Pharmaceuticals is the large dot.

Atea Pharmaceuticals competitors and peer comparison

How Atea Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Atea Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAVIRPeer medianRank in peer set
1-month return-10.6%-6.1%7th lowest of 21
6-month return-4.8%-22.1%8th highest of 21
Distance from 52-week high-38.1%-37.5%10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%2.4×38.3%-3.2%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%

Questions

Which companies are Atea Pharmaceuticals's closest peers?
The cockpit's peer set: GC Corp. (005250.KS), Swedencare (SECARE.ST), Foresee Pharmaceuticals (6576.TWO), Kitazato (368A.T), Inovio Pharmaceuticals (INO), Beihai Gofar Chuanshan Biological (600538.SS), Chongqing Hifuture Information Technology (002168.SZ), Ind-Swift Laboratories (INDSWFTLAB.NS).
How has Atea Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -4.8% against -22.1% for the median peer; over one year +32.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.